Rapamycin (Sirolimus) Cost in Mississippi

What Rapamycin (Sirolimus) Costs in Mississippi Right Now

The average cash-pay price for generic sirolimus at Mississippi retail pharmacies in 2026 is approximately $80 per month for a standard supply. That figure reflects a 30-tablet quantity of 1 mg tablets, the most common dispensing unit for both transplant maintenance and off-label weekly dosing protocols. Brand-name Rapamune from Pfizer carries a list price near $600 per month, though almost no one pays list price at a retail counter 1.

Retail Pharmacy Pricing Across the State

Pricing varies between independent pharmacies and large chains. Mississippi has a higher proportion of independent pharmacies than the national average, and these independents sometimes negotiate lower acquisition costs on generics. CVS, Walgreens, and Walmart locations in Jackson, Gulfport, and Hattiesburg typically list sirolimus between $70 and $95 for a 30-day supply without insurance. Requesting the pharmacy's cash price directly (rather than running a rejected insurance claim) can sometimes yield a lower number.

Compounded Sirolimus Pricing

Compounded sirolimus from a state-licensed 503A pharmacy costs about $120 per month in Mississippi. This option appeals to patients who need custom dosing (for example, a 5 mg weekly capsule instead of taking five 1 mg tablets). Compounding pharmacies may also offer topical rapamycin formulations for dermatologic use, such as facial angiofibromas in tuberous sclerosis complex, a use supported by published case series 2.

Why the Price Spread Is So Wide

Sirolimus pricing in Mississippi spans from roughly $60 at the low end (with a coupon at a high-volume chain) to $600 at full brand-name list price. Three factors explain that range.

Manufacturer List Price vs. Generic Competition

Pfizer's Rapamune has been off-patent since 2014. Multiple generic manufacturers (including Greenstone, Biocon, and Dr. Reddy's) now produce sirolimus tablets and oral solution. Generic competition has compressed the actual transaction price well below list 3. The FDA's Orange Book lists over a dozen approved ANDA holders for sirolimus as of 2026.

Pharmacy Benefit Manager Contracts

PBMs negotiate rebates with manufacturers that affect what a patient pays at the counter. If a PBM favors the brand (because of a larger rebate), the generic may paradoxically cost more on a formulary copay basis. Mississippi patients on commercial insurance should compare their copay to the GoodRx or RxSaver cash price before filling 4.

503A Compounding Overhead

Compounded sirolimus costs more than mass-manufactured generic tablets because 503A pharmacies produce patient-specific preparations in smaller batches. Quality-testing requirements add cost. A compounded preparation is not FDA-approved, but it is legal in Mississippi when dispensed pursuant to a valid prescription under Section 503A of the Federal Food, Drug, and Cosmetic Act 5.

Mississippi Medicaid and Sirolimus Coverage

Mississippi Medicaid does not cover sirolimus for off-label longevity or anti-aging indications. Coverage exists for FDA-approved transplant rejection prophylaxis when prescribed by a transplant center and supported by prior authorization. The Mississippi Division of Medicaid follows a preferred drug list (PDL) that includes generic sirolimus for transplant patients, but the prior authorization requirement is strict 6.

Transplant vs. Off-Label Coverage Logic

For transplant recipients, Medicaid typically covers sirolimus as a Tier 2 generic with prior auth. Documentation must include the transplant date, concomitant immunosuppressive regimen, and target trough levels. Off-label prescribing for longevity, geroprotection, or immune modulation falls outside Medicaid's covered indication list. No state Medicaid program in the U.S. Currently covers rapamycin for aging-related indications 7.

What Off-Label Patients Can Do

Patients seeking sirolimus for longevity in Mississippi must pay out of pocket. The $80 per month generic cash price or $120 compounded price represents the realistic baseline. Some patients reduce cost further by using manufacturer coupons or patient assistance programs (discussed below).

Insurance Coverage Beyond Medicaid

Commercial insurance plans active in Mississippi (Blue Cross Blue Shield of Mississippi, UnitedHealthcare, Aetna, Ambetter by Magnolia Health) generally cover sirolimus for transplant rejection prophylaxis. Coverage for off-label use is rare. A few high-end executive health plans have begun covering geroprotective prescriptions, but these represent a small fraction of the Mississippi market.

Prior Authorization Requirements

Most Mississippi commercial plans require prior authorization for sirolimus regardless of indication. The typical PA criteria include: confirmed organ transplant within the past 12 months or ongoing transplant maintenance, documented intolerance or contraindication to calcineurin inhibitors, and trough level monitoring every 1 to 3 months 8. Off-label PA requests are almost universally denied on first submission.

Appeals for Off-Label Coverage

Mississippi insurance regulations allow two levels of internal appeal and one external review. For off-label sirolimus, the strongest appeal cites the drug's established safety profile in transplant populations and emerging longevity data. The PEARL trial (Aging Cell, 2024; N=40) demonstrated that 6 mg weekly rapamycin over 48 weeks was well-tolerated in healthy older adults and reduced several aging biomarkers 9. An appeal citing PEARL and earlier immune-function data from Mannick et al. (2014, N=218), which showed low-dose mTOR inhibition improved influenza vaccine response in elderly subjects by approximately 20%, may warrant medical director review 10.

Discount Programs and Savings Cards

Several programs can reduce sirolimus costs for Mississippi patients paying out of pocket.

Pfizer Savings Programs

Pfizer offers a Rapamune copay card for commercially insured patients that reduces out-of-pocket cost to as low as $0 for eligible individuals. Patients without insurance do not qualify for the copay card but may apply to Pfizer's patient assistance program (Pfizer RxPathways), which provides free medication to households earning below 400% of the federal poverty level 11.

Pharmacy Discount Platforms

GoodRx, RxSaver, and SingleCare all list sirolimus coupons for Mississippi pharmacies. Typical coupon prices in 2026 range from $55 to $85 for 30 tablets of 1 mg. These coupons cannot be combined with insurance but often beat the insurance copay, particularly for patients with high-deductible health plans.

340B Program Access

Mississippi has 42 hospitals and federally qualified health centers (FQHCs) that participate in the federal 340B Drug Pricing Program. Eligible patients receiving care at a 340B-covered entity may access sirolimus at significantly reduced cost 12. The 340B price for sirolimus can be 50% to 80% below wholesale acquisition cost. Contact your local FQHC to ask if outpatient pharmacy services include 340B pricing.

Telehealth Prescribing in Mississippi

Mississippi permits telehealth prescribing of sirolimus. The state's telehealth parity law (Mississippi Code 83-9-351) requires commercial insurers to cover telehealth visits at the same rate as in-person visits. A physician licensed in Mississippi (or holding a Mississippi telemedicine license) can prescribe sirolimus after an appropriate evaluation. Several longevity medicine practices now offer rapamycin consultations via telehealth to Mississippi residents.

What a Telehealth Visit Typically Includes

A standard longevity-focused telehealth consultation for rapamycin involves: review of medical history and contraindications, baseline labs (CBC, CMP, fasting lipid panel, fasting glucose, HbA1c), discussion of dosing protocol (most commonly 3 to 6 mg once weekly for geroprotection), and a follow-up lab schedule at 4, 12, and 24 weeks 13. Initial consultation costs range from $150 to $350 depending on the practice.

Monitoring and Lab Costs

Ongoing monitoring adds to the total cost of rapamycin therapy. Sirolimus trough levels (drawn 24 hours post-dose for daily regimens, or pre-dose for weekly protocols) cost $25 to $75 at Quest Diagnostics or LabCorp locations in Mississippi. Lipid panels and CBCs are standard additions. The mTOR inhibitor class carries known risks of hyperlipidemia and mild cytopenias that require surveillance 14. Bassen et al. Reported that weekly low-dose rapamycin produced mean triglyceride increases of 15 to 20% in healthy adults, a finding consistent with the PEARL data 15.

Is Compounded Sirolimus Legal in Mississippi?

Yes. Compounded sirolimus is legal in Mississippi when dispensed by a pharmacy holding a valid Mississippi Board of Pharmacy license and operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. The pharmacy must compound the drug pursuant to a patient-specific prescription from a licensed prescriber. Mississippi does not impose additional state-level restrictions on 503A compounding beyond federal requirements 16.

503A vs. 503B: What Mississippi Patients Should Know

A 503A pharmacy compounds for individual patients with prescriptions. A 503B outsourcing facility compounds in bulk without patient-specific prescriptions and ships to healthcare facilities. Both are active in Mississippi. Patients ordering compounded sirolimus for personal use will typically work with a 503A pharmacy. Verify that the pharmacy is registered with the FDA and the Mississippi Board of Pharmacy before purchasing 17.

Total Monthly Cost Breakdown for Mississippi Patients

A realistic monthly budget for rapamycin therapy in Mississippi includes the drug cost plus monitoring and consultation fees.

Generic Tablet Route

Drug cost with coupon: $55 to $85. Quarterly labs (amortized monthly): $15 to $25. Telehealth follow-up (amortized monthly from quarterly visits): $30 to $60. Estimated total: $100 to $170 per month for the first year.

Compounded Route

Drug cost: $120. Quarterly labs (amortized monthly): $15 to $25. Telehealth follow-up (amortized monthly): $30 to $60. Estimated total: $165 to $205 per month for the first year.

These estimates assume off-label longevity use without insurance coverage. Transplant patients with Medicaid or commercial coverage will pay significantly less, often limited to a generic copay of $3 to $15 per fill 18.

Safety Considerations That Affect Cost Decisions

Choosing the cheapest sirolimus source is not always the best decision. The mTOR inhibitor class has a well-characterized adverse event profile that requires medical supervision.

Key Adverse Effects at Longevity Doses

The PEARL trial reported that 6 mg weekly rapamycin over 48 weeks produced no serious adverse events in 20 treated participants 19. Mild adverse effects included oral aphthous ulcers (15% of participants), transient lipid elevations, and one case of mild leukopenia that resolved without dose adjustment. Mannick et al. Reported similar tolerability with the mTOR inhibitor everolimus at low doses in a 218-patient trial, where the most common adverse event was mouth ulceration at 9.8% 20.

When to Avoid Rapamycin

Sirolimus is contraindicated in patients with active infections, uncontrolled hyperlipidemia (LDL >190 mg/dL untreated), or known hypersensitivity to sirolimus or its derivatives. The FDA label also warns against use in liver transplant and lung transplant populations due to increased mortality risk in those specific settings 21. Patients on strong CYP3A4 inhibitors (ketoconazole, voriconazole, clarithromycin) require dose reduction or avoidance due to dramatically increased sirolimus blood levels 22.

Dr. Matt Kaeberlein, a leading rapamycin researcher formerly at the University of Washington, has stated: "The safety data from PEARL and earlier studies suggest that intermittent low-dose rapamycin is far better tolerated than the daily high-dose regimens used in transplant medicine. But this does not mean it is risk-free, and medical supervision remains non-negotiable."

The Endocrine Society's 2023 Scientific Statement on aging interventions noted: "mTOR inhibitors show promise as geroprotective agents, but current evidence is insufficient to recommend population-wide use outside of clinical trials" 23.

Patients starting rapamycin in Mississippi should confirm their prescriber monitors CBC and lipids at baseline and every 3 months for the first year, with sirolimus trough levels checked if using daily dosing protocols, per the FDA-approved labeling guidance of maintaining troughs between 4 and 12 ng/mL for transplant patients 24.